… analyzed randomized controlled trials and systematic reviews if … For patients with previously
untreated MM and for candidates for … Data appropriate for meta-analysis were not available …

… for economic studies of multiple myeloma and survival for people with multiple myeloma in
… Differences exist between the systematic review and trial inclusion/exclusion criteria and …

… of combined data from randomized controlled trials (RCTs) will … The aim of this systematic
review and meta-analysis was to … number of clinical trials contributing to this meta-analysis is …

… (NMA) of efficacy and toxicity data from all existing randomized controlled trials (RCT) …
study population comprised of previously untreated patients with symptomatic Multiple Myeloma …

… used a systematic review to identify randomized controlled trials (… of the randomized phase
III trial SWOG S0777: bortezomib, … in patients (Pts) with previously untreated multiple myeloma …

… daratumumab; daratumumab plus bortezomib, melphalan, and … ,” “first diagnosed,” “previously
untreated,” “unsuitable for … Because of the small number of clinical trials comparing RVd …

… independently by 2 of us (SG and PK) to confirm final eligibility for qualitative and quantitative
synthesis using the following selection criteria: (1) all phase 3 randomized clinical trials …

… The goal of this systematic review and meta‐analysis was to … a systematic review and
meta‐analysis of clinical trials of bortezomib for patients with previously untreated myeloma and …

… VMP and Rd in large randomised controlled trials (RCTs). … up of the randomized phase III
trial SWOG S0777: bortezomib, … in patients (Pts) with previously untreated multiple myeloma …

… Bortezomib, lenalidomide and dexamethasone vs. … in patients (Pts) with previously
untreated multiple myeloma … Because this study is a systematic review, and not a meta-analysis…